Genfit S.A. (GNFT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genfit S.A. (GNFT) has a cash flow conversion efficiency ratio of -0.574x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.10 Million) by net assets ($52.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GNFT market cap overview for the company's overall valuation and market capitalisation.
Genfit S.A. - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Genfit S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genfit S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genfit S.A. ranked by their cash flow conversion efficiency. Explore Genfit S.A. (GNFT) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
B&G Foods Inc
NYSE:BGS
|
0.211x |
|
Al Aqar Healthcare Reit
KLSE:5116
|
0.019x |
|
GOCL Corporation Limited
NSE:GOCLCORP
|
-0.008x |
|
Khgears International Limited
TW:4571
|
0.072x |
|
CSLM Digital Asset Acquisition Corp III, Ltd
NASDAQ:KOYN
|
-0.001x |
|
Sino AG
F:XTP
|
N/A |
|
Shattuck Labs Inc
NASDAQ:STTK
|
-0.096x |
|
Pihlajalinna Oy
HE:PIHLIS
|
0.091x |
Annual Cash Flow Conversion Efficiency for Genfit S.A. (2004–2024)
The table below shows the annual cash flow conversion efficiency of Genfit S.A. from 2004 to 2024. View Genfit S.A. share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $69.22 Million | $15.55 Million | 0.225x | +127.54% |
| 2023-12-31 | $67.95 Million | $-55.43 Million | -0.816x | -6.15% |
| 2022-12-31 | $94.53 Million | $-72.64 Million | -0.768x | -191.60% |
| 2021-12-31 | $119.10 Million | $99.92 Million | 0.839x | -85.93% |
| 2020-12-31 | $-16.16 Million | $-96.37 Million | 5.963x | +1151.31% |
| 2019-12-31 | $84.06 Million | $-47.68 Million | -0.567x | +78.82% |
| 2018-12-31 | $20.94 Million | $-56.08 Million | -2.678x | -459.93% |
| 2017-12-31 | $104.23 Million | $-49.86 Million | -0.478x | -150.88% |
| 2016-12-31 | $142.80 Million | $-27.23 Million | -0.191x | +28.95% |
| 2015-12-31 | $55.42 Million | $-14.87 Million | -0.268x | -21.99% |
| 2014-12-31 | $70.43 Million | $-15.49 Million | -0.220x | +66.27% |
| 2013-12-31 | $14.09 Million | $-9.19 Million | -0.652x | +43.31% |
| 2012-12-31 | $6.83 Million | $-7.86 Million | -1.150x | +27.92% |
| 2011-12-31 | $4.46 Million | $-7.11 Million | -1.596x | -148.23% |
| 2010-12-31 | $8.39 Million | $-5.39 Million | -0.643x | -4415.44% |
| 2009-12-31 | $15.52 Million | $-221.00K | -0.014x | +93.83% |
| 2008-12-31 | $22.38 Million | $-5.16 Million | -0.231x | -21.55% |
| 2007-12-31 | $25.37 Million | $-4.81 Million | -0.190x | -202.28% |
| 2006-12-31 | $27.77 Million | $-1.74 Million | -0.063x | -150.16% |
| 2005-12-31 | $13.39 Million | $1.68 Million | 0.125x | -54.99% |
| 2004-12-31 | $14.00 Million | $3.89 Million | 0.278x | -- |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more